Insider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells $5,726,100.00 in Stock

Posted by Shane Hupp on May 4th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $572.61, for a total transaction of $5,726,100.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,808,586.36. The trade was a 34.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

James Edgemond also recently made the following trade(s):

On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $568.83, for a total transaction of $5,688,300.00.
On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The shares were sold at an average price of $575.85, for a total transaction of $209,609.40.
On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The shares were sold at an average price of $572.21, for a total transaction of $5,513,815.56.
On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.86, for a total transaction of $5,778,600.00.
On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.18, for a total transaction of $5,771,800.00.
On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.88, for a total transaction of $5,748,800.00.
On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.89, for a total transaction of $5,778,900.00.
On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00.
On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total transaction of $5,615,000.00.
On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total transaction of $5,931,700.00.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $570.40 on Monday. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $607.89. The firm has a market cap of $25.00 billion, a price-to-earnings ratio of 20.44, a P/E/G ratio of 1.62 and a beta of 0.60. The company’s 50 day moving average is $543.83 and its 200-day moving average is $498.27.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same quarter last year, the firm posted $6.19 earnings per share. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. Research analysts predict that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC grew its stake in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 64 shares during the last quarter. Citizens Financial Group Inc. RI boosted its stake in United Therapeutics by 61.4% during the first quarter. Citizens Financial Group Inc. RI now owns 691 shares of the biotechnology company’s stock worth $410,000 after buying an additional 263 shares in the last quarter. Fifth Third Bancorp boosted its stake in United Therapeutics by 35,842.9% during the first quarter. Fifth Third Bancorp now owns 164,978 shares of the biotechnology company’s stock worth $97,829,000 after buying an additional 164,519 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in United Therapeutics by 2.9% during the first quarter. Oregon Public Employees Retirement Fund now owns 8,840 shares of the biotechnology company’s stock worth $5,242,000 after buying an additional 251 shares in the last quarter. Finally, Frank Rimerman Advisors LLC acquired a new stake in United Therapeutics during the first quarter worth $230,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on UTHR shares. Bank of America lifted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 31st. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Morgan Stanley raised their price objective on shares of United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Finally, Raymond James Financial assumed coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $601.50.

View Our Latest Research Report on UTHR

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.